Canopy Growth's 30-day narrative centers on a fundamental disconnect between operational stabilization and market sentiment. The company reported Q4 FY2026 revenue growth of 10-14% year-over-year, signaling recovery in Canada's mature cannabis market, yet the stock declined 4.45% while broader indices gained, indicating investor skepticism persists despite improving fundamentals. The dominant bearish pressure stems from two competing forces. Speculative positioning around federal cannabis rescheduling has failed to sustain valuations, with analysts noting CGC "bought time, not a higher rating." Simultaneously, structural headwinds including regulatory fragmentation, margin compression, and competitive commoditization continue constraining the sector. The 0.39 average grade score reflects skepticism that current revenue momentum can overcome these legacy challenges. Forward-looking risks cluster around cannabis reform timing and execution. If rescheduling materializes before year-end, CGC could benefit as a primary exposure vehicle alongside TLRY. However, absent near-term legislative catalysts, the stock faces elevated structural risk relative to historical valuation levels, limiting upside momentum.